GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Cash From Other Investing Activities

Mabpharm (HKSE:02181) Cash From Other Investing Activities : HK$0.16 Mil (TTM As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Mabpharm Cash From Other Investing Activities?

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Mabpharm's cash from other investing activities for the six months ended in Dec. 2023 was HK$0.14 Mil. It means Mabpharm received HK$0.14 Mil from other investing activities. Mabpharm's cash from other investing activities for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.16 Mil.

Mabpharm Cash From Other Investing Activities Historical Data

The historical data trend for Mabpharm's Cash From Other Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mabpharm Cash From Other Investing Activities Chart

Mabpharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash From Other Investing Activities
Get a 7-Day Free Trial -132.25 206.15 -37.71 39.23 0.16

Mabpharm Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash From Other Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.98 41.02 -16.55 0.02 0.14

Mabpharm Cash From Other Investing Activities Calculation

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cash From Other Investing Activities for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabpharm Cash From Other Investing Activities Related Terms

Thank you for viewing the detailed overview of Mabpharm's Cash From Other Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Mabpharm (HKSE:02181) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mabpharm Ltd (HKSE:02181) » Definitions » Cash From Other Investing Activities
Comparable Companies
HKSE:01672 HKSE:02256 HKSE:06978 HKSE:02496 HKSE:02137 HKSE:06628 HKSE:06622 HKSE:01875 HKSE:01873 HKSE:01244 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Website
http://www.mabpharm.cn
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Executives
Guo Jianjun 2307 Founder of a discretionary trust who can infl
Asia Mabtech Limited
Asia Pacific Immunotech Venture Limited
Guo Family (ptc) Limited
Fortune-healthy Investment Limited
Link Best Capital Limited
Cdh Fund V, L.p.
Cdh Mabtech Limited
Cdh V Holdings Company Limited
China Diamond Holdings Company Limited
China Diamond Holdings V Limited

Mabpharm (HKSE:02181) Headlines

No Headlines